Blueprint Medicines
About
Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
- Cambridge,Massachusetts,United States
- 251 - 500
- http://www.blueprintmedicines.com
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $50M
- Industries
- Bioinformatics,Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2011
- Number Of Employee
- 251 - 500
- Operating Status
- Active
- Stock Symbol
- nasdaq:BPMC
- Legal Name
- Blueprint Medicines Corporation
Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 27, 2019 | Post-IPO Equity | $327.20M | — | — | — | Detail |
| Dec 11, 2017 | Post-IPO Equity | $325.50M | — | — | — | Detail |
| Mar 29, 2017 | Post-IPO Equity | $215.60M | — | — | — | Detail |
| Dec 6, 2016 | Post-IPO Equity | $134.50M | — | — | — | Detail |
| Apr 27, 2015 | IPO | $147M | — | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Partner Fund Management
|
Yes | Series C |
Eight Roads Ventures
|
Yes | Series Unknown |
Casdin Capital
|
— | Series C |
Cowen Group
|
— | Series C |
|
|
— | Series C |
|
|
— | Series C |
Perceptive Advisors
|
— | Series C |
RA Capital Management
|
— | Series C |
|
|
— | Series C |
Sabby Capital
|
— | Series C |
Employee Profiles
Acquisition
Blueprint Medicines has acquired 1 organizations. Their most recent acquisition was Lengo Therapeutics on Nov 29, 2021. They acquired Lengo Therapeutics for $250M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Nov 29, 2021
Lengo Therapeutics
|
Biotechnology | acquisition | $ 250M | Detail |
